Clinical Trial Update: Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

Extension Phase 2 study assessing safety and efficacy of Natalizumab in Japanese participants with Relapsing-Remitting Multiple Sclerosis; results posted Januar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2016-01-14